Astrazeneca plc ADR [AZN] stock is trading at $65.29, up 0.15%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The AZN shares have gain 2.26% over the last week, with a monthly amount drifted -16.13%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Astrazeneca plc ADR [NASDAQ: AZN] stock has seen the most recent analyst activity on November 06, 2024, when Deutsche Bank upgraded its rating to a Hold. Previously, Deutsche Bank downgraded its rating to Sell on September 13, 2024. On May 30, 2024, Goldman initiated with a Buy rating and assigned a price target of $97 on the stock. Deutsche Bank upgraded its rating to a Hold. Deutsche Bank downgraded its rating to a Sell. Morgan Stanley started tracking with a Overweight rating for this stock on January 23, 2024, and assigned it a price target of $85.
Astrazeneca plc ADR [AZN] stock has fluctuated between $60.47 and $87.68 over the past year. Currently, Wall Street analysts expect the stock to reach $84 within the next 12 months. Astrazeneca plc ADR [NASDAQ: AZN] shares were valued at $65.29 at the most recent close of the market. An investor can expect a potential return of 28.66% based on the average AZN price forecast.
Analyzing the AZN fundamentals
Astrazeneca plc ADR [NASDAQ:AZN] reported sales of 51.21B for the trailing twelve months, which represents a growth of 18.04%. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at 0.19%, Pretax Profit Margin comes in at 0.16%, and Net Profit Margin reading is 0.13%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.17 and Total Capital is 0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.82.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 64.75 points at the first support level, and at 64.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 65.76, and for the 2nd resistance point, it is at 66.24.
Ratios To Look Out For
For context, Astrazeneca plc ADR’s Current Ratio is 0.93. In addition, the Quick Ratio stands at 0.71 and the Cash Ratio stands at 0.24. Considering the valuation of this stock, the price to sales ratio is 3.95, the price to book ratio is 4.97 and price to earnings (TTM) ratio is 31.38.
